Eli Lilly's Orforglipron Study in Adolescents with Obesity Underway
Eli Lilly is conducting a study to evaluate the efficacy and safety of orforglipron in adolescents with obesity or related comorbidities.
Phase III
Endocrinology / Obesity
Status
Active
Sponsor
Eli Lilly
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
Eli Lilly's ongoing study of orforglipron in adolescents with obesity is significant as it targets a growing demographic with limited treatment options. Success in this trial could enhance their competitive positioning in the obesity treatment market, particularly against existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding efficacy and safety outcomes over the next 18 months.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.